![Reshma Rangwala](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 517 144 $ in data 31/05/2026
Reshma Rangwala is currently Chief Medical Officer & Head of Research at Karyopharm Therapeutics, Inc. since 2022.
Former positions include Chief Medical Officer at Aravive, Inc. from 2020 to 2022, Vice President-Medical at Genmab, Inc. from 2017 to 2020, and Executive Clinical Director at Merck & Co., Inc. from 2012 to 2017.
Education includes undergraduate studies at Duke University and a doctorate from The University of Cincinnati College of Medicine.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 14/05/2026 | 56.829 ( 0,25% ) | 517 144 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Direttore Tecnico/Scientifico/R&S | 01/04/2022 |
| Società | Posizione | Fine |
|---|---|---|
| ARAVIVE, INC. | Direttore Tecnico/Scientifico/R&S | 28/03/2022 |
Genmab, Inc.
 Genmab, Inc. Miscellaneous Commercial ServicesCommercial Services Creates and develops human antibodies for the treatment of life-threatening and debilitating diseases | Direttore Tecnico/Scientifico/R&S | 01/07/2020 |
| MERCK & CO., INC. | Direttore Tecnico/Scientifico/R&S | 01/05/2017 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 6 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genmab, Inc.
Genmab, Inc. Miscellaneous Commercial ServicesCommercial Services Creates and develops human antibodies for the treatment of life-threatening and debilitating diseases | Commercial Services |
The University of Cincinnati College of Medicine
 The University of Cincinnati College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Karyopharm Therapeutics, Inc.
 Karyopharm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation | Health Technology |
Aravive, Inc.
 Aravive, Inc. BiotechnologyHealth Technology Develops therapies for solid tumors and hematologic malignancies | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
